核转位在肿瘤发生发展中的研究进展

基础医学与临床 ›› 2020, Vol. 40 ›› Issue (8): 1119-1123.

核转位在肿瘤发生发展中的研究进展

周杰¹, 黄英辉^2*

1.陆军军医大学西南医院肿瘤科, 重庆 400038;
2.陆军军医大学预防医学院复合伤研究所, 重庆 400038

收稿日期:2020-04-10 修回日期:2020-06-18 出版日期:2020-08-05 发布日期:2020-07-29
通讯作者: ^*ikkyhuang@163.com
基金资助:
国家自然科学基金(81802783,81800468)

Research progress of nuclear-cytoplasmic translocation in the genesis and development of tumor

ZHOU Jie¹, HUANG Ying-hui^2*

1. Department of Oncology, Southwest Hospital;
2. Institute of Combined Injury, College of Preventive Medicine, Army Medical University, Chongqing 400038, China

Received:2020-04-10 Revised:2020-06-18 Online:2020-08-05 Published:2020-07-29
Contact: ^*ikkyhuang@163.com

摘要/Abstract

摘要： 核转位是导致基因异常定位的一个重要原因,该现象出现在肿瘤发展的各阶段,并与肿瘤的治疗及耐药密切相关。本文总结核转位通路的基本结构、生物学功能、调控机制,以及在肿瘤发生发展中的作用,旨在为探索新的抗肿瘤策略提供理论依据。

关键词: 核转位, 分子机制, 治疗, 研究进展

Abstract: Nuclear-cytoplasmic translocation is an important cause of abnormal gene localization, which occurs at various stages of tumor development and is closely related to tumor treatment and drug resistance. In this paper, the basic structure, biological function and regulatory mechanism of nuclear translocation are described, and the role of nuclear-cytoplasmic translocation in the genesis and development of tumors, as well as the progress in tumor therapy and drug resistance are further reviewed, in order to provide theoretical basis for exploring novel anti-tumor strategies.

Key words: nuclear-cytoplasmic translocation, molecular mechanism, therapy, research progress

中图分类号:

R730.23

周杰, 黄英辉. 核转位在肿瘤发生发展中的研究进展[J]. 基础医学与临床, 2020, 40(8): 1119-1123.

ZHOU Jie, HUANG Ying-hui. Research progress of nuclear-cytoplasmic translocation in the genesis and development of tumor[J]. Basic & Clinical Medicine, 2020, 40(8): 1119-1123.

参考文献

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018,68:7-30.
[2] Li FL, Liu JP, Bao RX, et al. Acetylation accumulates PFKFB3 in cytoplasm to promote glycolysis and protects cells from cisplatin-induced apoptosis[J]. Nat Commun, 2018,9:508. doi:10.1038/s41467-018-02950-5.
[3] Lin DH, Correia AR, Cai SW, et al. Structural and functional analysis of mRNA export regulation by the nuclear pore complex[J]. Nat Commun, 2018,9:2319. doi:10.1038/s41467-018-04459-3.
[4 ] Bui KH, von Appen A, DiGuilio AL, et al. Integrated structural analysis of the human nuclear pore complex scaffold[J]. Cell, 2013,155:1233-1243.
[5] Zhou M, Liu H, Xu X, et al. Identification of nuclear localization signal that governs nuclear import of BRD7 and its essential roles in inhibiting cell cycle progression[J]. J Cell Biochem, 2006,98:920-930.
[6] Xu D, Grishin NV, Chook YM. NESdb: a database of NES-containing CRM1 cargoes[J]. Mol Biol Cell, 2012,23:3673-3676.
[7] Tavolieri MV, Droppelmann CA, Campos-Melo D,et al. A novel overlapping NLS/NES region within the PH domain of Rho guanine nucleotide exchange factor(RGNEF) regulates its nuclear-cytoplasmic localization[J]. Eur J Cell Biol, 2019, 98: 27-35.
[8] Chook YM, Blobel G. Karyopherins and nuclear import[J]. Curr Opin Struct Biol, 2001,11:703-715.
[9] Kapinos LE, Huang B, Rencurel C, et al. Karyopherins regulate nuclear pore complex barrier and transport function[J]. J Cell Biol, 2017,216:3609-3624.
[10] Barbato S, Kapinos LE, Rencurel C, et al. Karyopherin enrichment at the nuclear pore complex attenuates Ran permeability[J]. J Cell Sci, 2020,133.doi:10.1242/jcs.238121.
[11] Kau TR, Way JC, Silver PA. Nuclear transport and cancer: from mechanism to intervention[J]. Nat Rev Cancer, 2004,4:106-117.
[12] Plafker K, Macara IG. Facilitated nucleocytoplasmic shuttling of the Ran binding protein RanBP1[J]. Mol Cell Biol, 2000,20:3510-3521.
[13] Gandhi UH, Senapedis W, Baloglu E, et al. Clinical implications of targeting XPO1-mediated nuclear export in multiple myeloma[J]. Clin Lymphoma Myeloma Leuk, 2018,18:335-345.
[14] Rahmani K, Dean DA. Leptomycin B alters the subcel-lular distribution of CRM1 (Exportin 1)[J]. Biochem Biophys Res Commun, 2017,488:253-258.
[15] Stelma T, Leaner VD. KPNB1-mediated nuclear import is required for motility and inflammatory transcription factor activity in cervical cancer cells[J]. Oncotarget, 2017,8:32833-32847.
[16] Cooper JP, Reynolds CP, Cho H, et al. Clinical development of fenretinide as an antineoplastic drug: pharm-acology perspectives[J]. Exp Biol Med (Maywood), 2017,242:1178-1184.
[17] Sorrentino G, Ruggeri N, Specchia V, et al. Metabolic control of YAP and TAZ by the mevalonate pathway[J]. Nat Cell Biol, 2014,16:357-366.
[18] Cyert MS. Regulation of nuclear localization during Signaling[J]. J Biol Chem, 276:20805-20808.
[19] de Polo A, Luo Z, Gerarduzzi C, et al. AXL receptor signalling suppresses p53 in melanoma through stabilization of the MDMX-MDM2 complex[J]. J Mol Cell Biol, 2017,9:154-165.
[20] Liu H, Zhang H, Wu X, et al. Nuclear cGAS suppresses DNA repair and promotes tumorigenesis[J]. Nature, 2018,563:131-136.
[21] Kim J, McMillan E, Kim HS, et al. XPO1-dependent nuclear export is a druggable vulnerability in kras-mutant lung cancer[J]. Nature, 2016,538:114-117.
[22] Wang J, Lu Q, Cai J, et al. Nestin regulates cellular redox homeostasis in lung cancer through the keap1-nrf2 feedback loop[J]. Nat Commun, 2019,10:5043. doi:10.1038/s41467-019-12925-9.
[23] Lee PC, Fang YF, Yamaguchi H, et al. Targeting PKCδ as a therapeutic strategy against heterogeneous mechanisms of EGFR inhibitor resistance in EGFR-mutant lung cancer[J]. Cancer Cell, 2018,34:954-969.

[1]	林柏柏, 钱风华, 钱义明, 赵雷, 孙旗, 褚梦瑶, 沈梦雯. 脓毒症并发毛细血管渗漏综合征的研究进展[J]. 基础医学与临床, 2022, 42(7): 1144-1147.
[2]	何丹, 阮中宝. 细胞外囊泡在心房颤动发病中的作用[J]. 基础医学与临床, 2022, 42(4): 671-674.
[3]	张爽, 李之凡, 钱杰, 吴娜琼. 腔内影像学方法评价降脂治疗对冠状动脉粥样硬化斑块影响的研究进展[J]. 基础医学与临床, 2022, 42(3): 366-371.
[4]	何啸, 胡为杰, 吕文昌, 任玉萍, 吴敏, 吴毅平, 张奇. 环状RNA在乳腺癌中作用的研究进展[J]. 基础医学与临床, 2022, 42(3): 507-511.
[5]	白静, 刘娜, 丁力, 雷丽, 倪瑞, 闫少春, 邵国. 放射治疗后宫颈癌组织内差异表达基因鉴定[J]. 基础医学与临床, 2022, 42(2): 215-220.
[6]	郭晓鹏, 幸兵, 马文斌. 垂体腺瘤免疫微环境及免疫治疗的研究进展[J]. 基础医学与临床, 2022, 42(1): 173-178.
[7]	万宝, 郇福奎, 赵宇, 陈欢, 耿松松, 阎辉, 张彦新. 局部晚期食管癌放射治疗两种固定方式的锁骨上区动度比较分析[J]. 基础医学与临床, 2022, 42(1): 131-135.
[8]	宋聪, 汪大圆, 沈明武, 史向阳. 核壳结构树状大分子的设计及其生物医学应用[J]. 基础医学与临床, 2022, 42(1): 15-25.
[9]	刘健. 基因治疗中的核酸药物及非病毒递送载体的研究进展[J]. 基础医学与临床, 2022, 42(1): 41-50.
[10]	张杨孙弯弯陆丽丹冯晓玲. 细胞自噬与凋亡相互作用分子机制的研究进展[J]. 基础医学与临床, 2021, 41(9): 1342-1346.
[11]	苏鹏飞蒋林章盈婧郭博马志强周炜洵于健春. 综合治疗79岁进展期胃癌1例[J]. 基础医学与临床, 2021, 41(7): 1043-1046.
[12]	王行行王导新. NETs与急性呼吸窘迫综合征的研究进展[J]. 基础医学与临床, 2021, 41(7): 1047-1051.
[13]	陈民佳汪晓月陈客宏陆红祥. 间充质干细胞治疗肺纤维化的研究进展[J]. 基础医学与临床, 2021, 41(7): 1056-1059.
[14]	杨庭楷文进纪志刚董德鑫叶子兴. 囊性嗜铬细胞瘤的诊断和治疗进展[J]. 基础医学与临床, 2021, 41(7): 1066-1070.
[15]	郭希, 赖莘秀, 杨媚滟, 李峤桢, 王思行, 宋章永. 抑制侵袭性真菌的新型分子及其作用靶点研究进展[J]. 基础医学与临床, 2021, 41(6): 904-908.